Thoratec Expecting Near-Term Completion Of Expanded LVAD Indication Trial
This article was originally published in The Gray Sheet
Executive Summary
Thoratec anticipates completing enrollment for its HeartMate VE left ventricular assist device (LVAD) clinical trial by the end of July, citing the fact that one of the study's predefined endpoints, 92 patient deaths, has almost been reached.